Equities analysts forecast that Aurora Cannabis Inc (NYSE:ACB) will post earnings of ($0.02) per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Aurora Cannabis’ earnings. The highest EPS estimate is $0.00 and the lowest is ($0.04). Aurora Cannabis reported earnings of $0.13 per share during the same quarter last year, which would suggest a negative year over year growth rate of 115.4%. The firm is expected to issue its next earnings report on Tuesday, September 24th.
On average, analysts expect that Aurora Cannabis will report full-year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.27) to ($0.16). For the next fiscal year, analysts forecast that the business will report earnings of ($0.03) per share, with EPS estimates ranging from ($0.08) to $0.04. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Aurora Cannabis.
ACB has been the subject of a number of recent analyst reports. Desjardins initiated coverage on Aurora Cannabis in a report on Thursday, April 25th. They set a “buy” rating and a $9.07 target price for the company. Seaport Global Securities initiated coverage on Aurora Cannabis in a report on Thursday, February 21st. They set a “neutral” rating for the company. GMP Securities restated a “hold” rating and set a $9.50 target price on shares of Aurora Cannabis in a report on Tuesday, February 12th. Cowen initiated coverage on Aurora Cannabis in a report on Tuesday, March 5th. They set an “outperform” rating for the company. Finally, TheStreet downgraded Aurora Cannabis from a “c” rating to a “d+” rating in a report on Monday, February 25th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $9.86.
Institutional investors and hedge funds have recently bought and sold shares of the business. Moisand Fitzgerald Tamayo LLC bought a new position in Aurora Cannabis in the first quarter worth $25,000. Financial Management Professionals Inc. raised its holdings in Aurora Cannabis by 586.3% in the first quarter. Financial Management Professionals Inc. now owns 3,061 shares of the company’s stock worth $28,000 after purchasing an additional 2,615 shares in the last quarter. Carroll Financial Associates Inc. bought a new position in Aurora Cannabis in the first quarter worth $27,000. Burt Wealth Advisors raised its holdings in Aurora Cannabis by 1,033.3% in the first quarter. Burt Wealth Advisors now owns 3,400 shares of the company’s stock worth $31,000 after purchasing an additional 3,100 shares in the last quarter. Finally, Oakworth Capital Inc. bought a new position in Aurora Cannabis in the first quarter worth $35,000. Institutional investors and hedge funds own 9.02% of the company’s stock.
About Aurora Cannabis
Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Read More: Technical Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.